2. Search Result
Search Result
Results for "

Arginine vasopressin V2 receptor

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

3

Peptides

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0049
    Argipressin
    5+ Cited Publications

    Arg8-vasopressin; AVP

    		 Vasopressin Receptor Neurological Disease Cancer
    Argipressin (Arg8-vasopressin) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1.
    Argipressin
  • HY-17000
    Tolvaptan
    Maximum Cited Publications
    19 Publications Verification

    OPC-41061

    		 Vasopressin Receptor Autophagy Cardiovascular Disease Endocrinology Cancer
    Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia .
    Tolvaptan
  • HY-18346
    Mozavaptan
    1 Publications Verification

    OPC-31260

    		 Vasopressin Receptor Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan
  • HY-W539944
    Argipressin acetate
    5+ Cited Publications

    Arg8-vasopressin acetate; AVP acetate

    		 Vasopressin Receptor Apoptosis Neurological Disease Cancer
    Argipressin (Arg8-vasopressin) (acetate) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1 .
    Argipressin acetate
  • HY-123593
    Mozavaptan hydrochloride
    1 Publications Verification

    OPC-31260 hydrochloride

    		 Vasopressin Receptor Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan hydrochloride
  • HY-162394
    Vasopressin V2 receptor antagonist 2

    		Vasopressin Receptor Metabolic Disease
    Vasopressin V2 receptor antagonist 2 (Compound 33) is an antagonist of the arginine vasopressin V2 receptor (V2R) with a Ki value of 6.2 nM. Vasopressin V2 receptor antagonist 2 can effectively reduce cAMP levels, thereby inhibiting the growth of renal cysts[1].
    Vasopressin V2 receptor antagonist 2
  • HY-18346R
    Mozavaptan (Standard)

    OPC-31260 (Standard)

    		 Vasopressin Receptor Reference Standards Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan (Standard) is the analytical standard of Mozavaptan. This product is intended for research and analytical applications. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan (Standard)
  • HY-157220
    Tolvaptan phosphate ester sodium

    		Vasopressin Receptor Cardiovascular Disease
    Tolvaptan phosphate ester sodium, a prodrug of Tolvaptan (HY-17000), can be used in the study of cardiac edema. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation .
    Tolvaptan phosphate ester sodium
  • HY-123593R
    Mozavaptan hydrochloride (Standard)

    OPC-31260 hydrochloride (Standard)

    		 Vasopressin Receptor Reference Standards Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan (hydrochloride) (Standard) is the analytical standard of Mozavaptan (hydrochloride). This product is intended for research and analytical applications. Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan hydrochloride (Standard)
  • HY-18346S
    Mozavaptan-d6

    OPC-31260-d6

    		 Isotope-Labeled Compounds Vasopressin Receptor Metabolic Disease Endocrinology Cancer
    Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan-d6
  • HY-17000R
    Tolvaptan (Standard)

    OPC-41061 (Standard)

    		 Reference Standards Vasopressin Receptor Autophagy Cardiovascular Disease Endocrinology Cancer
    Tolvaptan (Standard) is the analytical standard of Tolvaptan. This product is intended for research and analytical applications. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia .
    Tolvaptan (Standard)
  • HY-186040
    ASP-7035

    		Vasopressin Receptor Neurological Disease
    ASP-7035 (compound 55) is an arginine vasopressin V2 receptor agonist. ASP-7035 can be used in the research of nocturia .
    ASP-7035

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: